Overview

A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris

Status:
Completed

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

The primary objective is to assess the safety and tolerability of 200 mg of belumosudil administered orally once daily for 28 days.

Phase:

Phase 2

Details

Lead Sponsor:

Kadmon Corporation, LLC